UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~June 30, 2016~~March 31, 2017

Commission file number 1-9788


	LANDAUER, INC. (Exact Name of Registrant as Specified in Its Charter)

	Delaware	06-1218089
	(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)

	2 Science Road, Glenwood, IL 60425 (Address of Principal Executive Offices and Zip Code)

	Registrant’s Telephone Number, Including Area Code: (708) 755-7000

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [ X ] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [ X ] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, ~~or a~~ smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated ~~filer”~~filer,” “smaller reporting company,” and ~~“smaller reporting~~“emerging growth company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer	[ ]	Accelerated filer	[ X ]
Non-accelerated filer	[ ]	Smaller reporting company	[ ]
(Do not check if a smaller reporting company)		Emerging growth company	[ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [ X ]

As of ~~August~~May 4, ~~2016, 9,603,864~~2017, 9,639,863 shares of common stock, par value $0.10 per share, of the registrant were outstanding.

TABLE OF CONTENTS



PART I FINANCIAL INFORMATION

Item 1.	Financial Statements

		Consolidated Balance Sheets (Unaudited)	3

		Consolidated Statements of Operations (Unaudited)	4

		Consolidated Statements of Comprehensive Income (Unaudited)	5

		Consolidated Statement of Stockholders’ Equity (Unaudited)	6

		Consolidated Statements of Cash Flows (Unaudited)	7

		Notes to Consolidated Financial Statements (Unaudited)	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		18

Item 3.	Quantitative and Qualitative Disclosures About Market Risk		23

Item 4.	Controls and Procedures		24


PART II OTHER INFORMATION

Item 1.	Legal Proceedings		2625

Item 1A.	Risk Factors		2625

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		2625

Item 3.	Defaults Upon Senior Securities		2625

Item 4.	Mine Safety Disclosures		2625

Item 5.	Other Information		2625

Item 6.	Exhibits		2726


SIGNATURE			2827

PART I FINANCIAL INFORMATION

Item 1.Financial Statements

LANDAUER, INC. AND SUBSIDIARIES

Consolidated Balance Sheets (Unaudited)


(Dollars in Thousands)	June 30, 2016		September 30, 2015		March 31, 2017		September 30, 2016
Assets
Cash and cash equivalents	$	11,975	$	15,314	$	12,875	$	13,285
Receivables, net of allowances of $1,609 at June 30, 2016 and $1,556 at September 30, 2015		33,050		32,412
Receivables, net of allowances of $1,380 at March 31, 2017 and $1,296 at September 30, 2016						36,195		31,998
Inventories		5,820		7,035		6,026		5,670
Deferred income tax assets - current		4,983		4,871		2,014		2,098
Prepaid income taxes						862		764
Prepaid expenses and other current assets		2,122		2,121		3,707		2,187
Total current assets		57,950		61,753		61,679		56,002
Property, plant and equipment, at cost		108,233		104,322		108,939		105,237
Less accumulated depreciation and amortization		(62,097)		(57,955)		(62,389)		(58,820)
Property, plant and equipment, net		46,136		46,367		46,550		46,417
Equity in joint ventures		25,330		24,010		25,312		26,174
Goodwill		33,704		35,072		33,469		33,807
Intangible assets, net of accumulated amortization of $11,527 at June 30, 2016 and $38,662 at September 30, 2015		9,857		13,052
Dosimetry devices, net of accumulated depreciation of $6,029 at June 30, 2016 and $5,282 at September 30, 2015		3,385		3,562
Intangible assets, net of accumulated amortization of $12,060 at March 31, 2017 and $11,772 at September 30, 2016						8,786		9,297
Dosimetry devices, net of accumulated depreciation of $6,615 at March 31, 2017 and $6,197 at September 30, 2016						2,724		3,162
Deferred income tax assets		11,492		16,702		5,507		9,104
Other assets		6,816		8,226		6,481		6,853
Total assets	$	194,670	$	208,744	$	190,508	$	190,816

Liabilities
Accounts payable	$	2,931	$	5,773	$	2,482	$	3,012
Dividends payable		2,780		2,684		2,871		2,815
Deferred contract revenue		14,213		13,904		14,651		13,932
Accrued compensation and related costs		8,547		8,603		7,370		9,256
Accrued severance		448		972		128		302
Other accrued expenses		8,114		6,557		5,863		5,181
Total current liabilities		37,033		38,493		33,365		34,498
Long-term debt		112,300		133,385		105,100		109,100
Pension and postretirement obligations		20,609		20,508		25,166		24,833
Deferred income tax liabilities		112		270		109		86
Uncertain income tax liabilities		1,499		2,310		1,516		1,495
Other non-current liabilities		249		1,451		181		205
Total liabilities		171,802		196,417		165,437		170,217
Commitments and Contingencies

Stockholders' equity
Preferred stock, $0.10 par value per share, authorized 1,000,000 shares; none issued		-		-		-		-
Common stock, $0.10 par value per share, authorized 20,000,000 shares; 9,731,170 and 9,641,532 shares issued and outstanding at June 30, 2016 and September 30, 2015, respectively		973		964
Common stock, $0.10 par value per share, authorized 20,000,000 shares; 9,814,751 and 9,727,264 shares issued and outstanding at March 31, 2017 and September 30, 2016, respectively						981		973
Additional paid in capital		43,320		41,531		45,861		43,982
Accumulated other comprehensive loss		(12,215)		(13,741)		(16,714)		(15,266)
Accumulated deficit		(10,401)		(17,559)		(6,319)		(10,511)
Landauer, Inc. stockholders' equity		21,677		11,195		23,809		19,178
Noncontrolling interest		1,191		1,132		1,262		1,421
Total stockholders' equity		22,868		12,327		25,071		20,599
Total Liabilities and Stockholders' Equity	$	194,670	$	208,744	$	190,508	$	190,816

The accompanying notes are an integral part of these consolidated financial statements.


	Three Months Ended June 30,				Nine Months Ended June 30,				Three Months Ended March 31,				Six Months Ended March 31,
(Dollars in Thousands, Except per Share)	2016		2015		2016		2015		2017		2016		2017		2016
Revenues:
Service revenues	$	32,344	$	31,924	$	97,051	$	96,223	$	34,213	$	33,162	$	66,962	$	64,707
Product revenues		5,510		3,543		15,415		14,930		4,909		4,920		9,732		9,905
Total revenues		37,854		35,467		112,466		111,153		39,122		38,082		76,694		74,612

Costs and expenses:
Service costs		16,032		15,531		48,708		47,323		16,775		16,498		32,753		32,676
Product costs		2,304		1,290		5,970		5,860		2,030		1,829		3,989		3,666
Total cost of sales		18,336		16,821		54,678		53,183		18,805		18,327		36,742		36,342

Gross profit		19,518		18,646		57,788		57,970		20,317		19,755		39,952		38,270
Selling, general and administrative		11,805		13,535		36,606		41,088
Selling, general and administrative expense										12,508		12,538		24,701		24,801
Operating income		7,713		5,111		21,182		16,882		7,809		7,217		15,251		13,469
Equity in income of joint ventures		244		428		797		1,804		1,173		252		1,809		553
Interest expense, net		(703)		(1,080)		(2,765)		(2,997)		(609)		(1,129)		(1,403)		(2,062)
Other (expense) income, net		3,550		158		3,493		(76)

Other income (expense), net										71		103		(257)		(57)
Income before taxes		10,804		4,617		22,707		15,613		8,444		6,443		15,400		11,903
Income tax expense		3,382		481		7,074		3,271		3,091		2,005		5,467		3,692

Net income		7,422		4,136		15,633		12,342		5,353		4,438		9,933		8,211
Less: Net income attributed to noncontrolling interest		157		81		446		363		178		159		357		289
Net income attributed to Landauer, Inc.	$	7,265	$	4,055	$	15,187	$	11,979	$	5,175	$	4,279	$	9,576	$	7,922

Net income per share attributable to Landauer, Inc. shareholders:
Basic	$	0.76	$	0.42	$	1.59	$	1.26	$	0.54	$	0.45	$	1.00	$	0.83
Weighted average basic shares outstanding		9,531		9,509		9,523		9,476		9,561		9,518		9,550		9,483

Diluted	$	0.76	$	0.42	$	1.58	$	1.25	$	0.54	$	0.45	$	0.99	$	0.83
Weighted average diluted shares outstanding		9,564		9,534		9,555		9,503		9,595		9,550		9,589		9,516

The accompanying notes are an integral part of these consolidated financial statements.



	Three Months Ended June 30, 2016						Nine Months Ended June 30, 2016						Three Months Ended March 31, 2017						Six Months Ended March 31, 2017
(Dollars in Thousands)	Landauer, Inc.		Noncontrolling Interest		Total		Landauer, Inc.		Noncontrolling Interest		Total		Landauer, Inc.		Noncontrolling Interest		Total		Landauer, Inc.		Noncontrolling Interest		Total
Net income	$	7,265	$	157	$	7,422	$	15,187	$	446	$	15,633	$	5,175	$	178	$	5,353	$	9,576	$	357	$	9,933
Other comprehensive income:
Defined benefit pension and postretirement plans activity, net of taxes of $52 and $153, respectively		85		-		85		257		-		257
Unrealized gains (losses) on available-for-sale securities, net of taxes of $35 and $34, respectively		(195)		-		(195)		(187)		-		(187)
Foreign currency translation adjustment, net of taxes of $427 and $784, respectively		793		3		796		1,456		27		1,483
Other comprehensive income (loss):
Defined benefit pension and postretirement plans activity, net of taxes of ($71) and ($142), respectively														119		-		119		238		-		238
Unrealized gains (losses) on available-for-sale securities, net of taxes of $0														-		-		-		-		-		-
Foreign currency translation adjustment, net of taxes of ($232) and $271, respectively														701		53		754		(1,686)		14		(1,672)
Comprehensive income	$	7,948	$	160	$	8,108	$	16,713	$	473	$	17,186	$	5,995	$	231	$	6,226	$	8,128	$	371	$	8,499

	Three Months Ended June 30, 2015						Nine Months Ended June 30, 2015						Three Months Ended March 31, 2016						Six Months Ended March 31, 2016
(Dollars in Thousands)	Landauer, Inc.		Noncontrolling Interest		Total		Landauer, Inc.		Noncontrolling Interest		Total		Landauer, Inc.		Noncontrolling Interest		Total		Landauer, Inc.		Noncontrolling Interest		Total
Net income	$	4,055	$	81	$	4,136	$	11,979	$	363	$	12,342	$	4,279	$	159	$	4,438	$	7,922	$	289	$	8,211
Other comprehensive income:
Defined benefit pension and postretirement plans activity, net of taxes of $27 and $80, respecitvely		46		-		46		137		-		137
Unrealized gains (losses) on available-for-sale securities, net of taxes of $9		41		-		41		43		-		43
Foreign currency translation adjustment, net of taxes of ($184) and $1,873, respectively		220		7		227		(3,478)		(191)		(3,669)
Defined benefit pension and postretirement plans activity, net of taxes of ($76) and ($101), respectively														128		-		128		172		-		172
Unrealized losses on available-for-sale securities, net of taxes of ($22) and ($1), respectively														83		-		83		8		-		8
Foreign currency translation adjustment, net of taxes of ($519) and ($357), respectively														980		22		1,002		663		24		687
Comprehensive income	$	4,362	$	88	$	4,450	$	8,681	$	172	$	8,853	$	5,470	$	181	$	5,651	$	8,765	$	313	$	9,078

The accompanying notes are an integral part of these consolidated financial statements.


	Landauer, Inc. Stockholders' Equity														Landauer, Inc. Stockholders' Equity
(Dollars in Thousands)	Common Stock Shares		Common Stock		Addi-tional Paid in Capital		Accumulated Other Compre-hensive (Loss) Income		(Accumulated Deficit) Retained Earnings		Non- Controlling Interest		Total Stock- holders' Equity		Common Stock Shares		Common Stock		Addi- tional Paid in Capital		Accumulated Other Compre-hensive (Loss) Income		(Accumulated Deficit) Retained Earnings		Non- Controlling Interest		Total Stock- holders' Equity
September 30, 2015		9,641,532	$	964	$	41,531	$	(13,741)	$	(17,559)	$	1,132	$	12,327
September 30, 2016																9,727,264	$	973	$	43,982	$	(15,266)	$	(10,511)	$	1,421	$	20,599
Stock-based compensation arrangements		89,638		9		1,789		-		-		-		1,798		87,487		8		1,879		-		-		-		1,887
Dividends		-		-		-		-		(8,029)		(414)		(8,443)		-		-		-		-		(5,384)		(530)		(5,914)
Net income		-		-		-		-		15,187		446		15,633		-		-		-		-		9,576		357		9,933
Foreign currency translation adjustment, net of tax		-		-		-		1,456		-		27		1,483		-		-		-		(1,686)		-		14		(1,672)
Unrealized gains (losses) on available-for-sale securities, net of tax		-		-		-		(187)		-		-		(187)
Defined benefit pension and postretirement plans activity, net of tax		-		-		-		257		-		-		257		-		-		-		238		-		-		238
June 30, 2016		9,731,170	$	973	$	43,320	$	(12,215)	$	(10,401)	$	1,191	$	22,868
March 31, 2017																9,814,751	$	981	$	45,861	$	(16,714)	$	(6,319)	$	1,262	$	25,071

The accompanying notes are an integral part of these consolidated financial statements.



	Nine Months Ended June 30,				Six Months Ended March 31,
(Dollars in Thousands)	2016		2015		2017		2016
Cash flows from operating activities:
Net income	$	15,633	$	12,342	$	9,933	$	8,211
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		8,461		9,274		5,352		5,661
Equity in income of joint ventures		(797)		(1,804)		(1,809)		(553)
Dividends from joint ventures		1,195		1,144		1,341		1,195
Stock-based compensation and related net tax benefits		2,048		1,422		1,456		1,144
Current and long-term deferred taxes, net		3,639		769		3,307		1,076
Gain on disposition of business		(3,904)		-
Loss on sale, disposal and abandonment of fixed assets		368		142		17		12
Gain on investments		(558)		(159)		(281)		(221)
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable, net		(1,771)		4,393
Decrease (increase) in prepaid taxes		39		(606)
Increase in accounts receivable, net						(4,487)		(276)
Decrease in prepaid taxes						700		39
Increase in other operating assets, net		(298)		(594)		(1,065)		(842)
Decrease in accounts payable and other accrued liabilities		(1,083)		(3,366)		(1,248)		(2,779)
Decrease in other operating liabilities, net		(753)		(1,246)
Increase in other operating liabilities, net						722		143
Net cash provided by operating activities		22,219		21,711		13,938		12,810

Cash flows from investing activities:
Acquisition of property, plant and equipment		(6,845)		(6,224)		(4,557)		(4,278)
Proceeds from disposition of business		10,089		-
Payment of transaction expenses associated with divestiture of business						-		(472)
Other investing activities, net		551		(467)		(554)		(1,232)
Net cash provided by (used in) investing activities		3,795		(6,691)
Net cash used in investing activities						(5,111)		(5,982)

Cash flows from financing activities:
Long-term borrowings - loan		13,500		26,300		3,500		11,000
Long-term borrowings - repayment		(34,585)		(25,500)		(7,500)		(18,400)
Dividends paid to stockholders		(7,933)		(13,237)		(5,328)		(5,286)
Other financing activities, net		(417)		(462)		(72)		(155)
Net cash used in financing activities		(29,435)		(12,899)		(9,400)		(12,841)

Effects of foreign currency translation		82		(441)		163		(88)
Net (decrease) increase in cash and cash equivalents		(3,339)		1,680
Net decrease in cash and cash equivalents						(410)		(6,101)
Opening balance - cash and cash equivalents		15,314		6,761		13,285		15,314
Ending balance - cash and cash equivalents	$	11,975	$	8,441	$	12,875	$	9,213

Accrued capital spending included in accounts payable and other accrued liabilities	$	477	$	993	$	509	$	783

The accompanying notes are an integral part of these consolidated financial statements.

As used herein, the terms “Company,” “Landauer,” “we,” “us,” and “our” refer collectively to Landauer, Inc. and its subsidiaries through which its various businesses are conducted.

The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements.

The consolidated financial statements include the accounts of the Company, its subsidiaries and variable interest entities in which the Company has a controlling financial interest. All intercompany balances and transactions have been eliminated in consolidation. Entities in which the Company does not have a controlling financial interest, but is considered to have significant influence, are accounted for on the equity method.

We believe that we have included all normal recurring adjustments necessary for a fair presentation of the results for the interim period. Operating results for the three and ~~nine month periods~~six months ended ~~June 30~~March 31, ~~2016~~2017 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, ~~2016.~~2017.

These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, ~~2015~~2016 (the “Form 10-K”) and other financial information filed with the Securities and Exchange Commission (the “SEC”). The September 30, ~~2015~~2016 balance sheet data was derived from audited financial statements but does not include all disclosures required by U.S. GAAP.

The accounting policies followed by the Company are set forth in the Form 10-K, and there have been no changes to the accounting policies for the ~~nine month~~six-month period ended ~~June 30, 2016.~~

The Company divested its Medical Products business in May 2016 and received cash proceeds of approximately $10.1 million, net of cash assumed by the acquirer and net of cash paid for transaction expenses. The Company recognized a $3.9 million pre-tax gain on sale from the disposition of this business. The Company has evaluated whether this divestiture qualifies as a discontinued operation pursuant to FASB Accounting Standards Codification 205-20 “Discontinued Operations.” The Company has concluded that the divestiture of the Medical Products business does not represent a strategic shift and is not material to the Company’s financial results and is therefore not considered a discontinued operation.

In June 2014, the Financial Accounting Standards Board (“FASB”) issued new guidance on accounting for share-based payments requiring a specific performance target to be achieved in order for employees to become eligible to vest in the awards when that performance target may be achieved after the requisite service period for the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period for which the requisite service has already been rendered. The Company adopted the updated standard in the first quarter of fiscal 2017 with no significant impact on its financial statements.

In April 2015, the FASB issued new guidance on a customer’s accounting for fees paid in a cloud computing arrangement (“CCA”). Under the new standard, customers will apply the same criteria as vendors to determine whether a CCA contains a software license or is solely a service contract. The Company adopted the updated standard prospectively in the first quarter of fiscal 2017 with no significant impact on its financial statements.

In May 2014, the ~~Financial Accounting Standards Board (“FASB”)~~FASB issued new guidance for recognizing revenue from contracts with customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. In July 2015, the FASB deferred the effective date of the new revenue standard by one year. Public companies would now be required to adopt the new guidance for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The FASB decided to allow earlier adoption of the new revenue standard, but not earlier than the original effective date. This guidance is effective for the Company in the first quarter of fiscal 2019. The Company is currently evaluating the impact that adoption of this guidance will have on its results of operations, financial position and liquidity.

~~In June 2014,~~ To date, the ~~FASB issued new guidance on accounting for share-based payments requiring~~Company has formed a ~~specific performance target~~committee to ~~be achieved in order for employees to become eligible to vest~~evaluate the impact and is in the awards when that performance target may be achieved after the requisite service period for the award. This update further clarifies that compensation cost should be recognized in the period in which it becomes probable that the performance target will be achieved and should represent the compensation cost attributable to the period for which the requisite service has already been rendered. This guidance is effective for the Company in the first quarterinitial stages of ~~fiscal 2017. Early adoption is permitted. The Company is currently evaluating the impact that adoption of this guidance will have on its results of operations, financial position and liquidity.~~

In April 2015, the FASB issued new guidance on the presentation of debt issuance costs. This update requires a company to present debt issuance costs related to a recognized debt liability in the balance sheet as a direct deduction from the carrying amount of the related debt liability, consistent with the presentation of debt discounts. Currently, debt issuance costs are presented as a deferred asset. The recognition and measurement requirements will not change as a result of this guidance. The update requires retrospective application and represents a change in accounting principle. This guidance is effective for the Company in the first quarter of fiscal 2017, with early adoption permitted. The Company does not expect the adoption of this guidance will have a material impact on its results of operations, financial position and liquidity.evaluation.

In July 2015, the FASB issued new guidance on simplifying the measurement of inventory. This update requires a company to measure inventory at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance is effective for the Company in the first quarter of fiscal 2018 and should be applied prospectively with early adoption permitted. The Company is currently evaluating the impact this guidance will have on its results of operations, financial position and liquidity.

In November 2015, the FASB issued new guidance on the presentation of deferred income taxes. This update requires a company to present deferred tax liabilities and assets as noncurrent in a classified statement of financial position rather than the current requirement to separate deferred income tax liabilities and assets into current and noncurrent amounts. This guidance is effective for the Company in the first quarter of fiscal 2018, with early adoption permitted. The Company does not expect the adoption of this guidance will have a material impact on its results of operations, financial position and liquidity.

In February 2016, the FASB issued new guidance on the accounting treatment for leases. This guidance will require all leases with durations greater than twelve months to be recognized on the balance sheet of the lessee. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or finance. Classification will be based on criteria that are largely similar to those applied in current lease accounting, but without explicit bright lines. This guidance is effective for the Company in the first quarter of fiscal 2020, although early adoption is permitted. The Company is currently evaluating the impact that adoption of this guidance will have on its results of operations, financial position and liquidity.

In March 2016, the FASB issued new guidance to improve the accounting for share-based payments. This standard makes several modifications to Topic 718 related to the accounting for forfeitures, employer tax withholding on share-based compensation and the financial statement presentation of excess tax benefits or deficiencies. The guidance also clarifies the statement of cash flows presentation for certain components of share-based awards. The standard is effective for the Company in the first quarter of fiscal 2018, although early adoption is permitted. The Company is currently evaluating the impact that adoption of this guidance will have on its results of operations, financial position and liquidity.

In June 2016, the FASB issued new guidance to introduce a new model for recognizing credit losses on financial instruments based on an estimate of current expected credit losses. The update replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to inform credit loss estimates. The update is effective for the Company in the first quarter of fiscal 2020, although early adoption is permitted. The Company is currently evaluating the effect that this update will have on its financial statements and related disclosures.

In August 2016, the FASB issued an Accounting Standards Update (“ASU”) to provide cash flow statement guidance for certain cash receipts and payments, including (a) debt prepayment or extinguishment costs; (b) contingent consideration payments made after a business combination; (c) insurance settlement proceeds; (d) distributions from equity method investees; (e) beneficial interests in securitization transactions and (f) application of the predominance principle for cash receipts and payments with aspects of more than one class of cash flows. The update is effective for the Company in the first quarter of fiscal 2018. The Company is currently evaluating the effect that this update will have on its financial statements and related disclosures.

In November 2016, the FASB issued amendments to current guidance related to the classification and presentation of changes in restricted cash in the Statement of Cash Flows. The update is effective for the Company in the first quarter of fiscal 2019, and early adoption is permitted. The Company is currently evaluating the impact that this update will have on its financial statements and related disclosures.

No other new accounting pronouncement issued or effective during the fiscal year had, or is expected to have, a material impact on the Consolidated Financial Statements.

The Company estimates the fair value of assets and liabilities in accordance with the framework established by the authoritative guidance for fair value measurements. The framework is based on the inputs used in valuation, gives the highest priority to quoted prices in active markets and requires that observable inputs be used in the valuations when available. The disclosure of fair value estimates in the fair value accounting guidance hierarchy is based on whether the significant inputs into the valuation are observable. In determining the level of the hierarchy in which the estimate is disclosed, the highest priority is given to unadjusted quoted prices in active markets and the lowest priority to unobservable inputs that reflect the Company’s significant market assumptions. The level in the fair value hierarchy within which the fair value measurement is reported is based on the lowest level input that is significant to the measurement in its entirety.

Financial assets measured at fair value on a recurring basis are summarized below:

Fair Value Measurements at June 30, 2016
(Dollars in Thousands)
Level 1

Level 2

Level 3
Asset Category

Cash equivalents
$
439

$
-

$
-
Mutual funds

3,496

-

-
Available-for-sale securities

-

6

-
Total financial assets at fair value
$
3,935

$
6

$
-

Fair Value Measurements at September 30, 2015
(Dollars in Thousands)
Level 1

Level 2

Level 3
Asset Category

Cash equivalents
$
272

$
-

$
-
Mutual funds

3,237

-

-
Available-for-sale securities

-

1,763

-
Total financial assets at fair value
$
3,509

$
1,763

$
-



	Fair Value Measurements at March 31, 2017
(Dollars in Thousands)	Level 1		Level 2		Level 3
Asset Category
Cash equivalents	$	547	$	-	$	-
Mutual funds		4,360		-		-
Total financial assets at fair value	$	4,907	$	-	$	-

	Fair Value Measurements at September 30, 2016
(Dollars in Thousands)	Level 1		Level 2		Level 3
Asset Category
Cash equivalents	$	453	$	-	$	-
Mutual funds		3,687		-		-
Total financial assets at fair value	$	4,140	$	-	$	-

Following is a description of each category in the fair value hierarchy and the financial assets and liabilities of the Company that were included in each category at ~~June 30, 2016~~March 31, 2017 and September 30, ~~2015,~~2016, measured on a recurring basis.

The Level 1 financial assets were comprised of investments in trading securities, which are reported in other long-term assets. The investments are held in a Rabbi trust for benefits under the Company’s deferred compensation plan. Under the plan, participants designate investment options to serve as the basis for measurement of the notional value of their accounts. The investments include a money market fund and mutual funds that are publicly traded. The fair values of the shares or underlying securities of these funds are based on quoted market prices.

The Level 2 financial assets are long-term investments consisting primarily of fixed income mutual funds, classified as available-for-sale securities. These investments are reported in other long-term assets. The investments in fixed income mutual funds are valued based on the net asset value of the underlying securities as provided by the investment account manager. The investments are not restricted or subject to a lockup and may be redeemed on demand. Notice within a certain period of time prior to redemption is not required.

The Company’s long-term debt is classified as Level 2. The carrying amount of the Company’s long-term debt is the approximated fair value, as the stated interest rates were variable in relation to prevailing market rates.

The Company had no material assets or liabilities that were measured at fair value on a non-recurring basis during the nine months ended June 30, 2016 or fiscal year ended September 30, 2015. There were no transfers between fair value hierarchy levels during these periods.

Basic net income per share was computed by dividing net income available to common stockholders for the period by the weighted average number of shares of common stock outstanding during the period. Diluted net income per share was computed by dividing net income available to common stockholders for the period by the weighted average number of shares of common stock that would have been outstanding assuming dilution from stock-based compensation awards during the period.



		Three Months Ended June 30,				Nine Months Ended June 30,					Three Months Ended March 31,				Six Months Ended March 31,
(Dollars in Thousands, Except per Share)	(Dollars in Thousands, Except per Share)	2016		2015		2016		2015		(Dollars in Thousands, Except per Share)	2017		2016		2017		2016
Basic Net Income per Share:
Net income attributed to Landauer, Inc.		$	7,265	$	4,055	$	15,187	$	11,979		$	5,175	$	4,279	$	9,576	$	7,922
Less: Income allocated to unvested restricted stock			20		20		59		67			15		21		38		39
Net income available to common stockholders		$	7,245	$	4,035	$	15,128	$	11,912		$	5,160	$	4,258	$	9,538	$	7,883
Basic weighted average shares outstanding			9,531		9,509		9,523		9,476			9,561		9,518		9,550		9,483
Net income per share - Basic		$	0.76	$	0.42	$	1.59	$	1.26		$	0.54	$	0.45	$	1.00	$	0.83

Diluted Net Income per Share:
Net income attributed to Landauer, Inc.		$	7,265	$	4,055	$	15,187	$	11,979		$	5,175	$	4,279	$	9,576	$	7,922
Less: Income allocated to unvested restricted stock			20		20		59		67			15		21		38		39
Net income available to common stockholders		$	7,245	$	4,035	$	15,128	$	11,912		$	5,160	$	4,258	$	9,538	$	7,883
Basic weighted average shares outstanding			9,531		9,509		9,523		9,476			9,561		9,518		9,550		9,483
Effect of dilutive securities			33		25		32		27			34		32		39		33
Diluted weighted averages shares outstanding			9,564		9,534		9,555		9,503			9,595		9,550		9,589		9,516
Net income per share - Diluted		$	0.76	$	0.42	$	1.58	$	1.25		$	0.54	$	0.45	$	0.99	$	0.83

Dividends declared per share		$	0.275	$	0.275	$	0.83	$	1.100
Dividends paid per share											$	0.275	$	0.275	$	0.55	$	0.55

On ~~May 12, 2016,~~February 16, 2017, the Company declared a regular quarterly cash dividend in the amount of $0.275 per ~~share for the third quarter of fiscal 2016.~~share. The dividends were paid on ~~July 5, 2016~~April 4, 2017 to shareholders of record as of ~~June~~March 17, ~~2016.~~2017.

The components of net periodic benefit cost for pension and other benefits were as follows:



Pension Benefits	Three Months Ended June 30,				Nine Months Ended June 30,				Three Months Ended March 31,				Six Months Ended March 31,
(Dollars in Thousands)	2016		2015		2016		2015		2017		2016		2017		2016
Interest cost	$	392	$	364	$	1,177	$	1,092	$	353	$	393	$	705	$	785
Expected return on plan assets		(373)		(396)		(1,120)		(1,188)		(387)		(374)		(775)		(747)
Amortization of net loss		141		85		422		253		190		140		380		281
Net periodic benefit cost	$	160	$	53	$	479	$	157	$	156	$	159	$	310	$	319

Other Benefits	Three Months Ended June 30,				Nine Months Ended June 30,				Three Months Ended March 31,				Six Months Ended March 31,
(Dollars in Thousands)	2016		2015		2016		2015		2017		2016		2017		2016
Service cost	$	15	$	13	$	45	$	38	$	16	$	15	$	32	$	30
Interest cost		10		8		29		24		8		9		17		19
Amortization of net gain		(3)		(12)		(11)		(36)		-		(4)		-		(8)
Net periodic benefit cost	$	22	$	9	$	63	$	26	$	24	$	20	$	49	$	41

The Company, under the IRS minimum funding standards, has no required contributions to make to its defined benefit pension plan during fiscal ~~2016.~~2017.

The Company sponsors a 401(k) retirement savings plan covering substantially all of the U.S. full-time employees in the Company’s Radiation Measurement segment as well as substantially all of the employees in the Company’s Medical Physics segment, and prior to its divestiture, the Medical Products ~~segments, which provides for certain employer matching contributions.~~segment. The Company also maintains a supplemental defined contribution plan for certain executives, which allows participating executives to make voluntary deferrals and provides for employer contributions at the discretion of the Company. Amounts expensed for Company contributions under these plans during the three months ended ~~June 30,~~March 31, 2017 and 2016 were $488 and ~~2015 were $494 and $500,~~$499, respectively. Amounts expensed for Company contributions under these plans during the ~~nine~~six months ended ~~June 30,~~March 31, 2017 and 2016 were $1,031 and ~~2015 were $1,412 and $1,349,~~$918, respectively.

Changes in the carrying amount of goodwill, by reportable segment, for the ~~nine~~six months ended

(Dollars in Thousands)

Radiation Measurement

Medical
Physics

Medical
Products

Total
Balance as of September 30, 2015

Goodwill

$
11,002

$
22,611

$
65,527

$
99,140
Accumulated impairment losses

-

-

(64,068)

(64,068)
Balance as of September 30, 2015

$
11,002

$
22,611

$
1,459

$
35,072
Effects of foreign currency - Goodwill

91

-

(784)

(693)
Effects of foreign currency - Accumulated impairment losses

-

-

769

769
Decrease related to dispositions - Goodwill

-

-

(64,743)

(64,743)
Decrease related to dispositions - Accumulated impairment losses

-

-

63,299

63,299
Balance as of June 30, 2016

Goodwill

$
11,093

$
22,611

$
-

$
33,704
Accumulated impairment losses

-

-

-

-
Balance as of June 30, 2016

$
11,093

$
22,611

$
-

$
33,704



(Dollars in Thousands)	Radiation Measurement		Medical Physics		Total

Balance as of September 30, 2016	$	11,196	$	22,611	$	33,807
Currency translation adjustment		(338)		-		(338)
Balance as of March 31, 2017	$	10,858	$	22,611	$	33,469

The Company had no accumulated impairment losses as of March 31, 2017 and September 30,2016.



	June 30, 2016								March 31, 2017
(Dollars in Thousands)	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Accumulated Intangibles Impairment Charge		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Customer lists	$	16,917	$	10,145	$	6,772	$	-	$	16,691	$	10,637	$	6,054
Trademarks and tradenames		133		-		133		-		133		-		133
Licenses and patents		3,757		825		2,932		-		3,465		866		2,599
Other intangibles		577		557		20		-		557		557		-
Intangible assets	$	21,384	$	11,527	$	9,857	$	-	$	20,846	$	12,060	$	8,786



	September 30, 2015								September 30, 2016
(Dollars in Thousands)	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Accumulated Intangibles Impairment Charge		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Customer lists	$	43,131	$	33,716	$	9,415	$	18,657	$	16,982	$	10,436	$	6,546
Trademarks and tradenames		2,181		2,051		130		1,498		133		-		133
Licenses and patents		5,825		2,338		3,487		665		3,397		779		2,618
Other intangibles		577		557		20		-		557		557		-
Intangible assets	$	51,714	$	38,662	$	13,052	$	20,820	$	21,069	$	11,772	$	9,297

Identifiable intangible assets with finite lives are amortized over their estimated useful lives. Intangible asset amortization expense was ~~$453~~$385 and ~~$1,576~~$771 for the three and ~~nine~~six months ended ~~June 30, 2016,~~March 31, 2017, respectively, and was ~~$560~~$568 and ~~$1,681~~$1,123 for the three and ~~nine~~six months ended ~~June 30, 2015,~~March 31, 2016, respectively.

Accumulated elements of other comprehensive loss, net of tax, are included in the stockholders’ equity section of the condensed consolidated balance sheets. Changes in each component for the ~~nine~~six months ended ~~June 30~~March 31, 2017 and 2016 are as follows:



(Dollars in Thousands)	Foreign Currency Translation Adjustments		Unrealized Gains and Losses on Available-for-Sale Securities		Pension and Postretirement Plans		Comprehensive (Loss) Income		Foreign Currency Translation Adjustments		Unrealized Gains and Losses on Available-for-Sale Securities		Pension and Postretirement Plans		Comprehensive (Loss) Income
Balance at September 30, 2015	$	(5,468)	$	259	$	(8,532)	$	(13,741)
Balance at September 30, 2016									$	(4,696)	$	-	$	(10,570)	$	(15,266)
Other comprehensive (loss) income before reclassifications		1,456		147		-		1,603		(1,686)		-		-		(1,686)
Amounts reclassified from accumulated other comprehensive (loss) income		-		(334)		257		(77)		-		-		238		238
Net current period other comprehensive (loss) income		1,456		(187)		257		1,526		(1,686)		-		238		(1,448)
Balance at June 30, 2016	$	(4,012)	$	72	$	(8,275)	$	(12,215)
Balance at March 31, 2017									$	(6,382)	$	-	$	(10,332)	$	(16,714)



(Dollars in Thousands)	Foreign Currency Translation Adjustments		Unrealized Gains and Losses on Available-for-Sale Securities		Pension and Postretirement Plans		Comprehensive (Loss) Income		Foreign Currency Translation Adjustments		Unrealized Gains and Losses on Available-for-Sale Securities		Pension and Postretirement Plans		Comprehensive (Loss) Income
Balance at September 30, 2014	$	(2,493)	$	166	$	(7,821)	$	(10,148)
Balance at September 30, 2015									$	(5,468)	$	259	$	(8,532)	$	(13,741)
Other comprehensive (loss) income before reclassifications		(3,478)		151		-		(3,327)		663		97		-		760
Amounts reclassified from accumulated other comprehensive (loss) income		-		(108)		137		29		-		(89)		172		83
Net current period other comprehensive (loss) income		(3,478)		43		137		(3,298)		663		8		172		843
Balance at June 30, 2015	$	(5,971)	$	209	$	(7,684)	$	(13,446)
Balance at March 31, 2016									$	(4,805)	$	267	$	(8,360)	$	(12,898)

The tables below present the impact on net income of significant amounts reclassified out of each component of accumulated other comprehensive loss:



Pension and Postretirement Plans (1)	Three Months Ended June 30,				Nine Months Ended June 30,				Three Months Ended March 31,				Six Months Ended March 31,
(Dollars in Thousands)	2016		2015		2016		2015		2017		2016		2017		2016
Amortization of net loss	$	137	$	73	$	410	$	217	$	190	$	204	$	380	$	273
Total before tax		137		73		410		217		190		204		380		273
Provision for income taxes		52		27		153		80		71		76		142		101
Total net of tax	$	85	$	46	$	257	$	137	$	119	$	128	$	238	$	172

(1)These accumulated other comprehensive loss components are included in the computation of net periodic benefit costs (refer to Note 5 of the Notes to Consolidated Financial Statements for additional details regarding employee benefit plans).



Unrealized Gains and Losses on Available-for-Sale Securities	Three Months Ended June 30,				Nine Months Ended June 30,				Three Months Ended March 31,				Six Months Ended March 31,
(Dollars in Thousands)	2016		2015		2016		2015		2017		2016		2017		2016
Realized gains on available-for-sale securities into earnings (1)	$	(288)	$	-	$	(393)	$	(99)	$	-	$	-	$	-	$	(105)
Total before tax		(288)		-		(393)		(99)		-		-		-		(105)
Provision for income taxes (2)		(43)		9		(59)		9		-		-		-		(16)
Total net of tax	$	(245)	$	9	$	(334)	$	(108)	$	-	$	-	$	-	$	(89)

(1)This amount is reported in Interest ~~expense,~~Expense, net on the Consolidated Statements of Operations

(2)This amount is reported in Income ~~tax expense~~Tax Expense (Benefit) on the Consolidated Statements of Operations

The effective tax rates for the three months ended ~~June 30,~~March 31, 2017 and 2016 were 36.6% and ~~2015 were 31.3% and 10.4%~~31.1%, respectively. The increase in the effective tax rate was primarily due to an overall increase in quarterly pre-tax book income relating to the sale of the Medical Products business which decreased the rate benefit for the realization of an unrecognized tax benefit. Also driving the rate increase was the mix of taxable earnings between ~~taxing jurisdictions.~~jurisdictions and tax law changes that impacted the prior year. The effective tax rates for the ~~nine~~six months ended ~~June 30,~~March 31, 2017 and 2016 were 35.5% and ~~2015 were 31.2% and 21.0%~~31.0%, respectively. The increase in the effective tax rate was primarily due to ~~higher permanent differences related to foreign dividends,~~ the mix of earnings between jurisdictions with differing tax rates and ~~increased pre-tax book income relating to~~tax law changes that impacted the ~~sale~~timing of recognition of certain credits in the ~~Medical Products business.~~prior year. The Company believes it is reasonably possible that ~~$698~~$570 of unrecognized tax benefits will be realized in fiscal year 2017.

The May 2016 sale of the Medical Products business, comprised of IZI Medical Products, LLC (“IZI”) and Ilumark GmbH (“Ilumark”), resulted in an ordinary tax loss on the sale of IZI and a capital tax loss on the sale of Ilumark. The ordinary loss on IZI is largely driven by the loss on disposal of intangibles, which converted into a net operating loss carryforward of approximately $50.0 to $60.0 million ($17.5 to $21.0 million tax effected). The Company expects to fully utilize the net operating loss as an offset to future ordinary income. The sale of Ilumark generated an estimated capital loss carryforward of approximately $600 ($210 net of tax) which can be offset against future capital gains. The Company does not expect to have any significant capital gains in the next five years, the carryforward period for capital losses, and has recorded a valuation allowance through its third quarter of fiscal 2016 annual estimated tax rate.

~~The~~In fiscal year 2017, the Company is organized into ~~three~~two reportable business segments: Radiation Measurement ~~Medical Physics~~ and Medical ~~Products.~~Physics. As disclosed in ~~Note 1 to~~ the ~~Consolidated Financial Statements,~~Form 10-K for the fiscal period ended September 30, 2016, the Medical Products business was divested in May ~~2016 which resulted in a reduction in~~2016; accordingly, there were no reportable revenues and operating income for the three and ~~nine~~six month periods ended ~~June 30, 2016 and the elimination of assets as of June 30, 2016~~March 31, 2017 for ~~the~~that reportable segment. These segments reflect the manner in which the Company’s businesses are currently managed and represent an aggregation of services and products based on type of customer and how the businesses are marketed. For more information regarding the nature of the Company’s services and products, see Note 16 of the Notes to Consolidated Financial Statements in the Form 10-K.

The following tables summarize financial information for each reportable segment:



	Three Months Ended June 30,				Nine Months Ended June 30,				Three Months Ended March 31,				Six Months Ended March 31,
(Unaudited, Dollars in Thousands)	2016		2015		2016		2015
(Dollars in Thousands)									2017		2016		2017		2016
Revenues by segment:
Radiation Measurement	$	27,492	$	24,143	$	77,716	$	77,880	$	28,692	$	25,520	$	56,324	$	50,224
Medical Physics		9,562		8,926		28,948		25,971		10,430		10,033		20,370		19,386
Medical Products		800		2,398		5,802		7,302		-		2,529		-		5,002
Consolidated revenues	$	37,854	$	35,467	$	112,466	$	111,153	$	39,122	$	38,082	$	76,694	$	74,612

	Three Months Ended June 30,				Nine Months Ended June 30,				Three Months Ended March 31,				Six Months Ended March 31,
(Unaudited, Dollars in Thousands)	2016		2015		2016		2015
(Dollars in Thousands)									2017		2016		2017		2016
Operating income (loss) by segment:
Radiation Measurement	$	10,294	$	7,604	$	29,161	$	26,402	$	11,409	$	9,969	$	22,641	$	18,867
Medical Physics		756		1,143		2,452		2,082		672		918		1,351		1,696
Medical Products		141		375		1,063		953		-		432		-		922
Corporate		(3,478)		(4,011)		(11,494)		(12,555)		(4,272)		(4,102)		(8,741)		(8,016)
Consolidated operating income	$	7,713	$	5,111	$	21,182	$	16,882	$	7,809	$	7,217	$	15,251	$	13,469

The Company has a minority interest in Yamasato, Fujiwara, Higa & Associates, Inc. doing business as Aquila. The Company provides dosimetry parts to Aquila for its military contract. The Company also has a 50% equity interest in Nagase-Landauer, Ltd. (“Nagase”), a radiation measurement company in Japan.



	Three Months Ended June 30,				Nine Months Ended June 30,				Three Months Ended March 31,				Six Months Ended March 31,
(Dollars in Thousands)	2016		2015		2016		2015		2017		2016		2017		2016
Sales to Aquila	$	2,653	$	1	$	3,067	$	3,674	$	2,933	$	18	$	5,501	$	414
Purchases from Aquila		201		165		405		196		30		214		104		204



(Dollars in Thousands)	June 30, 2016		September 30, 2015		March 31, 2017		September 30, 2016
Amounts in accounts receivable	$	4,318	$	2,795	$	4,069	$	1,910
Amounts in accounts payable		492		284		114		320



	Three Months Ended June 30,				Nine Months Ended June 30,				Three Months Ended March 31,				Six Months Ended March 31,
(Dollars in Thousands)	2016		2015		2016		2015		2017		2016		2017		2016
Sales to Nagase	$	1,180	$	169	$	3,474	$	924	$	1,002	$	1,196	$	2,243	$	2,294
Purchases from Nagase		123		472		817		934		319		99		629		694



(Dollars in Thousands)	June 30, 2016		September 30, 2015		March 31, 2017		September 30, 2016
Amounts in accounts receivable	$	428	$	769	$	294	$	288
Amounts in accounts payable		11		33		52		23

Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of the Company’s unaudited consolidated financial condition and results of operations should be read in conjunction with the annual audited consolidated financial statements and related notes thereto included in the Company’s Form 10-K. The following discussion includes forward-looking statements that involve certain risks and uncertainties. For additional information regarding forward-looking statements and risk factors, see “Forward-Looking Statements” herein and Item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, ~~2015.~~2016.

The preparation of the interim consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the interim consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Critical accounting policies are those that are most important to the portrayal of a company’s financial condition and results of operations and that require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. The Company bases its estimates, judgments and assumptions on historical experience and other relevant factors that are believed to be reasonable under the circumstances. In any given reporting period, the Company’s actual results may differ from the estimates, judgments and assumptions used in preparing the consolidated financial statements.

Comparison of the ~~third~~second fiscal quarter ended ~~June 30, 2016~~March 31, 2017 and the ~~third~~second fiscal quarter ended ~~June 30, 2015~~March 31, 2016

Revenues for the ~~third~~second fiscal quarter of ~~2016~~2017 were ~~$37.9~~$39.1 million, an increase of ~~$2.4~~$1.0 million, or ~~6.8%~~2.6%, compared to revenues of ~~$35.5~~$38.1 million for the ~~third~~second fiscal quarter of ~~2015.~~2016. Revenues in the Radiation Measurement segment increased ~~$3.4~~$3.2 million, which was primarily due to product sales to the ~~military and the Company’s joint venture in Japan. Unfavorable foreign currency translation rates partially reduced revenues by $0.2 million.~~military. Revenues in the Medical Physics segment increased ~~$0.7~~$0.4 million, due to increased imaging services. Revenues in the Medical Products segment decreased ~~$1.6~~$2.5 million due to the divestiture of this business in May 2016.

Gross profit was ~~51.6%~~51.9% for the ~~third~~second fiscal quarter of ~~2016, compared with 52.6% for~~2017, which is unchanged from the ~~third~~second fiscal quarter of ~~2015.~~ ~~Gross profit decreased for the third fiscal quarter of 2016 as compared to the third fiscal quarter of 2015 due to an increase in personnel expenses in the Medical Physics segment.~~2016.

Selling, general and administrative expenses for the ~~third~~second fiscal quarter of ~~2016~~2017 were ~~$11.8~~$12.5 million, ~~a decrease of $1.7 million, or 12.6%, compared with $13.5 million for~~ the ~~third~~same amount as the second fiscal quarter of ~~2015.~~ 2016. Operating expenses in Corporate and the Radiation Measurement segment decreased $1.2 million primarily due to lower professional fees and due to the reduction in expenses resulting from the Radon divestiture during fiscal 2015. In addition, operating expenses in the Medical Products segment decreased ~~$0.7~~$1.1 million due to the divestiture of the business in May ~~2016.~~2016, offset by a $0.6 million increase in Corporate and Radiation Measurement expenses and a $0.5 million increase in Medical Physics expenses. Corporate and Radiation Measurement operating expenses increased $0.6 million primarily due to a $0.3 million increase in selling and marketing expenses and $0.3 million of proxy contest expenses for the 2017 Annual Meeting of Stockholders. The increase in operating expenses in Medical Physics was driven by an increase in personnel expenses.

Operating income for the ~~third~~second fiscal quarter of ~~2016~~2017 was ~~$7.7~~$7.8 million, compared with operating income of ~~$5.1~~$7.2 million for the ~~third~~second fiscal quarter of ~~2015.~~2016. Operating income increased due primarily to the gross profit on the higher ~~product sales~~military sales.

The effective tax rates for the second fiscal quarter of 2017 and 2016 were 36.6% and 31.1%, respectively. The increase in the effective tax rate was primarily due to the ~~decrease~~mix of taxable earnings between jurisdictions and tax law changes that impacted the timing of recognition of certain credits in ~~selling, general and administrative expenses.~~

~~Other income for~~ the ~~third fiscal quarter of 2016 includes a $3.9 million pre-tax gain on sale of the Medical Products business that was divested in May 2016 for net cash proceeds of $10.1 million.~~

The effective tax rates for the third fiscal quarter of 2016 and 2015 were 31.3% and 10.4%, respectively. The increase in the effective tax rate was primarily due to an overall increase in quarterly pre-tax book income relating to the sale of the Medical Products business which decreased the rate benefit for the realization of an unrecognized tax benefit. Also driving the rate was the mix of earnings between taxing jurisdictions.

Net income attributed to Landauer for the ~~third~~second fiscal quarter of ~~2016~~2017 was ~~$7.3~~$5.2 million, compared with net income of ~~$4.1~~$4.3 million in the ~~third~~second fiscal quarter of ~~2015.~~2016. The increase in net income was driven by ~~the gain on sale of the Medical Products business and~~ stronger operating margins and higher equity earnings from joint ventures, partially offset by a higher effective tax ~~rate~~.rate.

Radiation Measurement revenues for the ~~third~~second fiscal quarter of ~~2016~~2017 were ~~$27.5~~$28.7 million, an increase of ~~$3.4~~$3.2 million, or ~~14.1%~~12.5%, compared with ~~$24.1~~$25.5 million for the ~~third~~second fiscal quarter of ~~2015.~~2016. The growth in revenues was primarily due to product sales to the military. During the third fiscal quarter of 2016, the Company was awarded a military order from the National Guard of the United States for the Radwatch personal in-field radiation monitoring system. Approximately ~~$2.5~~$2.9 million of the increase in revenues resulted from the ~~first~~ shipment of products for the National Guard order and $0.8 million of the increase resulted from higher product sales to the Company’s joint venture in Japan. The growth in international revenues substantially offset the $0.8 million reduction in revenues resulting from the Radon business that was divested in September 2015.order.

Operating income for the ~~third~~second fiscal quarter of ~~2016~~2017 increased to ~~$10.3~~$11.4 million from ~~$7.6~~$10.0 million for the ~~third~~second fiscal quarter of ~~2015~~2016 due to the gross profit on the increased product ~~sales and due to lower operating expenses. Personnel expenses have decreased as a result of the management restructuring in the fourth fiscal quarter of 2015.~~sales.

Medical Physics revenues for the ~~third~~second fiscal quarter of ~~2016~~2017 were ~~$9.6~~$10.4 million, an increase of ~~$0.7~~$0.4 million, or ~~7.9%~~4.0%, compared with ~~$8.9~~$10.0 million for the ~~third~~second fiscal quarter of ~~2015.~~2016. Imaging services revenue increased by ~~$0.5~~$0.6 million, or ~~19.2%~~18.8%, driven by higher demand for the Company’s solutions for The Joint Commission’s new Diagnostic Imaging requirements that became effective for hospitals and ambulatory care centers on July 1, 2015.

Operating income for the ~~third~~second fiscal quarter of ~~2016~~2017 was ~~$0.8~~$0.7 million, compared to ~~$1.1~~$0.9 million for the ~~third~~second fiscal q~~uarter~~quarter of ~~2015.~~2016. The decrease in operating income was primarily due to an increase in personnel ~~expenses~~.expenses.

Medical Products revenues decreased ~~to $0.8~~$2.5 million ~~for the third fiscal quarter of 2016 from $2.4 million for the third fiscal quarter of 2015~~ as a result of the divestiture that occurred in May 2016.

Medical Products operating income decreased ~~to $0.1 million for the third fiscal quarter of 2016 from~~ $0.4 million ~~for the third fiscal quarter of 2015~~ due to the May 2016 divestiture.

Corporate selling, general and administrative expenses for the ~~third~~second fiscal quarter of ~~2016~~2017 were ~~$3.5~~$4.3 million, ~~a decrease~~an increase of ~~$0.5~~$0.2 million, or ~~12.5%~~4.9%, compared to ~~$4.0~~$4.1 million for the ~~third~~second fiscal quarter of ~~2015.~~2016. The ~~decrease~~increase was due to ~~lower professional fees~~. a $0.3 million increase in proxy expenses for the 2017 Annual Meeting of Stockholders.

Comparison of the ~~nine~~six months ended ~~June 30, 2016~~March 31, 2017 and the ~~nine~~six months ended ~~June 30, 2015~~March 31, 2016

Revenues for the first ~~nine~~six months of fiscal ~~2016~~2017 were ~~$112.5~~$76.7 million, an increase of ~~$1.3~~$2.1 million, or ~~1.2%~~2.8%, compared to revenues of ~~$111.2~~$74.6 million for the first ~~nine~~six months of fiscal ~~2015.~~2016. Revenues in the Radiation Measurement segment ~~decreased $0.2~~increased $6.1 million, which was primarily due to the Radon business that was divested in September 2015, resulting in a $3.9 million reduction in revenues. In addition, unfavorable foreign currency translation rates reduced revenues by $2.0 million. Domestic Radiation Measurement services revenues increased 2.5% and product sales to the ~~Company’s joint venture~~military and growth in ~~Japan increased $2.4 million, partially offsetting the impact of the Radon business divestiture and the foreign currency rates. Reve~~international revenues. ~~nues~~Revenues in the Medical Physics segment increased ~~$2.9 millio~~$1.0 million, n, due ~~primarily~~ to increased imaging ~~services.~~services. Revenues in the Medical Products segment decreased ~~$1.5~~$5.0 million due to the divestiture of this business ~~during~~in May 2016.

Gross profit was ~~51.4%~~52.1% for the first ~~nine~~six months of fiscal 2017, compared with 51.3% for the first six months of fiscal 2016. Gross profit increased for the first six months of 2017 as compared to the first six months of fiscal 2016 ~~compared with 52.2% for the first nine months of fiscal 2015. Gross profits in the Radiation Measurement segment have increased to 62.1% for the first nine months of fiscal 2016~~ ~~from 61.5% for the first nine months of fiscal 2015. However, consolidated gross profits have decreased~~ due primarily to the ~~growth~~increase in ~~Medical Physics revenues which realize lower gross profits than Radiation Measurement.~~ product sales to the military.

Selling, general and administrative expenses for the first ~~nine~~six months of fiscal ~~2016~~2017 were ~~$36.6~~$24.7 million, a decrease of ~~$4.5~~$0.1 million, or ~~10.9%~~0.4%, compared with ~~$41.1~~$24.8 million for the first ~~nine~~six months of fiscal 2015. Operating expenses in Corporate and the Radiation Measurement segment decreased $3.5 million primarily due to professional fees and due to the reduction in expenses resulting from the Radon business divestiture.2016. Operating expenses in the Medical Products segment decreased ~~$0.8~~$2.2 million due to the divestiture of ~~this~~the business ~~during~~in May ~~2016.~~2016, partially offset by a $1.5 million increase in Corporate and Radiation Measurement expenses and a $0.6 million increase in Medical Physics expenses. Corporate and Radiation Measurement operating expenses increased $1.5 million primarily due to $0.5 million of proxy contest expenses for the 2017 Annual Meeting of Stockholders, a $0.3 million increase in research and development expenses for the Verifii digital dosimetry platform, a $0.3 million increase in selling and marketing expenses and a $0.3 million increase in stock-based compensation expense. The increase in operating expenses in Medical Physics was driven by an increase in personnel expenses.

Operating income for the first ~~nine~~six months of ~~fiscal 2016~~2017 was ~~$21.2~~$15.3 million, compared with operating income of ~~$16.9~~$13.5 million for the first ~~nine~~six months of ~~fiscal 2015.~~2016. Operating income increased due primarily to the ~~$4.5 million decrease in selling, general and administrative expenses.~~

~~Equity in income of joint ventures for~~gross profit on the ~~first~~ ~~nine months of fiscal 2016 was $0.8 million compared with $1.8 million for the first nine months of fiscal 2015. Product sales by our joint venture, Aquila, were impacted by the timing of~~higher military sales. In addition, ~~equity in income of joint ventures decreased due~~the Company successfully appealed the real estate taxes for fiscal 2011 and 2012, and as a result, is expected to ~~lower profit on product sales to our joint venture in Japan.~~

~~Other income for the third fiscal quarter of 2016 includes~~receive a ~~$3.9~~$0.6 million ~~pre-tax gain on sale of the Medical Products business that was divested in May 2016 for net cash proceeds of $10.1 million.~~ refund.

The effective tax rates for the first ~~nine~~six months of fiscal 2017 and fiscal 2016 were 35.5% and ~~2015 were 31.2% and 21.0%~~31.0%, respectively. The increase in the effective tax rate was primarily due to ~~higher permanent differences related to foreign dividends,~~ the mix of taxable earnings between jurisdictions ~~with differing~~and tax ~~rates and increased pre-tax book income relating to~~law changes that impacted the ~~sale~~timing of recognition of certain credits in the ~~Medical Products business.~~prior year.

Net income attributed to Landauer for the first ~~nine~~six months of fiscal ~~2016~~2017 was ~~$15.2~~$9.6 million, ~~an increase~~compared with net income of ~~$3.2 million, or 26.7%, from $12.0~~$7.9 million in the first ~~nine~~six months of ~~fiscal 2015.~~2016. The increase in net income was driven by ~~the gain on sale of the Medical Products business and~~ stronger operating margins, partially offset by a higher effective tax rate.

Radiation Measurement revenues for the first six months of fiscal 2017 were $56.3 million, an increase of $6.1 million, or 12.2%, compared with $50.2 million for the first six months of fiscal 2016. The growth in revenues was primarily due to product sales to the military and higher international revenues. During the third fiscal quarter of 2016, the Company was awarded a military order from the National Guard of the United States for the Radwatch personal in-field radiation monitoring system. Approximately $5.1 million of the increase in revenues resulted from the shipment of products for the National Guard order. International revenues increased $0.5 million due primarily to higher product sales.

Operating income for the first six months of fiscal 2017 increased to $22.6 million from $18.9 million for the first six months of fiscal 2016 due to the gross profit on the increased product sales and due to the refund of real estate taxes for fiscal 2011 and 2012.

~~Radiation Measurement revenues for the first nine months of fiscal 2016 were $77.7 million, a decrease of $0.2 million, or 0.3%, compared with $77.9 million for the first nine months of fiscal 2015.~~ The decrease in revenues was primarily due to the Radon business that was divested in September 2015, resulting in a $3.9 million reduction in revenues. In addition, unfavorable foreign currency translation rates reduced revenues by $2.0 million. Domestic Radiation Measurement services revenues increased 2.5% and product sales to the Company’s joint venture in Japan increased $2.4 million, partially offsetting the impact of the Radon business divestiture and the foreign currency rates.

Operating income for the first nine months of fiscal 2016 was $29.2 million compared with operating income of $26.4 million for the first nine months of fiscal 2015. Operating income increased due to lower ~~selling, general and administrative expenses.~~

Medical Physics revenues for the first ~~nine~~six months of fiscal ~~2016~~2017 were ~~$28.9~~$20.4 million, an increase of ~~$2.9~~$1.0 million, or ~~11.2%~~5.2%, compared with ~~$26.0~~$19.4 million for the first ~~nine~~six months of fiscal ~~2015.~~2016. Imaging services revenue increased by ~~$2.0~~$1.2 million, or ~~27.4%~~19.7%, driven by higher demand for the Company’s solutions for The Joint Commission’s new Diagnostic Imaging requirements that became effective for hospitals and ambulatory care centers on July 1, 2015.

Operating income for the first ~~nine~~six months of fiscal ~~2016~~2017 was ~~$2.5~~$1.4 million, compared to ~~$2.1~~ $1.7 million for the first ~~nine~~six months of fiscal ~~2015.~~2016. The ~~increase~~decrease in operating income was primarily due to ~~the gross profit on the increased sales~~.an increase in personnel expenses.

Medical Products revenues decreased ~~to $5.8~~$5.0 million ~~for the first nine months of fiscal 2016 from $7.3 million for the first nine months of fiscal 2015~~ as a result of the divestiture that occurred in May 2016.

Medical Products ~~had~~ operating income ~~of $1.1 million for the first nine months of fiscal 2016 versus operating income of~~decreased $0.9 million ~~for~~due to the ~~first nine months of fiscal 2015.~~May 2016 divestiture.

Corporate selling, general and administrative expenses for the first ~~nine~~six months of fiscal ~~2016~~2017 were ~~$11.5~~$8.7 million, ~~a decrease~~an increase of ~~$1.1~~$0.7 million, or 8.7%, compared to ~~$12.6~~$8.0 million for the first ~~nine~~six months of fiscal ~~fiscal 2015.~~2016. The ~~decrease~~increase was due to ~~lower professional fees, including audit and legal fees~~a $0.5 million increase in proxy expenses for the 2017 Annual Meeting of Stockholders as well as a $0.3 million increase in stock-based compensation expense..

The Company’s principal source of liquidity is operating cash flows supplemented by borrowings under its credit facility. The Company’s cash-generating capability is one of its fundamental strengths and provides it with substantial financial flexibility in meeting operating and investing needs.



	Nine Months Ended June 30,				Six Months Ended March 31,
(Dollars in Thousands)	2016		2015		2017		2016
Net cash provided by (used in):
Operating activities	$	22,219	$	21,711	$	13,938	$	12,810
Investing activities		3,795		(6,691)		(5,111)		(5,982)
Financing activities		(29,435)		(12,899)		(9,400)		(12,841)
Effect of foreign currency translation		82		(441)		163		(88)
Net (decrease) increase in cash and cash equivalents	$	(3,339)	$	1,680
Net decrease in cash and cash equivalents					$	(410)	$	(6,101)

Cash provided by operating activities for the first ~~nine~~six months of fiscal ~~2016~~2017 was ~~$22.2~~$13.9 million, an increase of ~~$0.5~~$1.1 million over the same fiscal period in ~~2015.~~2016. The increase was primarily due to lower spending in professional service fees and lower cash interest payments on ~~selling, general and administrative expenses.~~long-term borrowings compared to the prior year.

Cash ~~provided by~~used in investing activities for the first ~~nine~~six months of fiscal ~~2016~~2017 was ~~$3.8~~$5.1 million, ~~an increase~~a change of ~~$10.5~~$0.9 million over the same fiscal period of ~~2015.~~2016. The ~~increase~~change was primarily due to ~~the proceeds received of $10.1 million from~~transaction expenses related to the disposition of the ~~Medical Products business.~~Radon business which were paid in fiscal 2016.

Cash used in financing activities for the first ~~nine~~six months of fiscal ~~2016~~2017 was ~~$29.4~~$9.4 million, ~~an increase~~a change of ~~$16.5~~$3.4 million over the same fiscal period of ~~2015.~~2016. The ~~increase~~change was primarily due to ~~higher~~lower net repayments of debt ~~facilitated by~~compared to the ~~cash proceeds received from the disposition of the Medical Products and Radon businesses.~~prior year. In addition, the Company expects to pay down debt over the next four to five years as it realizes ~~its $17.5 million to $21.0 million~~a cash tax benefit of approximately $16.0 million resulting from the disposal of the Medical Products business. As of ~~June 30, 2016,~~March 31, 2017, the Company had ~~$62.7~~$34.9 million of unused availability under its current ~~$175.0~~$140.0 million credit facility, which the Company believes provides adequate liquidity to meet its current and anticipated obligations.During the first nine months of fiscal 2016 and 2015, the Company paid cash dividends of $7.9 million and $13.2 million, respectively. The Company reduced its dividend payment from $0.55 per share to $0.275 per share during the third fiscal quarter of 2015.

The Company expects to meet short-term liquidity requirements (including capital expenditures) through net cash from operating activities and cash on hand. The Company was in compliance with all covenants under the credit facility as of ~~June 30, 2016.~~March 31, 2017. The Company currently intends to use excess cash to continue to pay down the long-term debt balance. The debt facility expires August 2, 2018.

See Note 2 to the Consolidated Financial Statements in Item 1 of Part I of this Form 10-Q.

There have been no material changes, outside of the ordinary course of business, in the Company’s outstanding contractual obligations since the end of fiscal year ~~2015~~2016 through ~~June 30, 2016.~~March 31, 2017.

Certain matters contained in this report constitute forward-looking statements that are based on certain assumptions and involve certain risks and uncertainties. These include the following, without limitation: assumptions, risks and uncertainties associated with the Company’s future performance; the Company’s development and introduction of new technologies and products in general; the ability to protect and utilize the Company’s intellectual property; events or circumstances which result in an impairment of ~~assets, including but not limited to, goodwill and identifiable intangible~~ assets; continued customer acceptance of the InLight technology; the adaptability of optically stimulated luminescence (“OSL”) technology to new platforms and formats; military and other government funding for the purchase of certain of the Company’s equipment and services; the impact on sales and pricing of certain customer group purchasing arrangements; changes in spending or reimbursement for ~~medical products or~~ services; the costs associated with the Company’s research and business development efforts; the usefulness of older technologies and related licenses and intellectual property; the effectiveness of and costs associated with the Company’s IT platform enhancements and investments in cyber security enhancements; the anticipated results of operations of the Company and its subsidiaries or joint ventures; valuation of the Company’s long-lived assets or reporting units relative to future cash flows; changes in pricing of services and products; changes in postal and delivery practices; the Company’s business plans; anticipated revenue and cost growth; the ability to integrate the operations of acquired businesses and to realize the expected benefits of acquisitions; the risks associated with conducting business internationally; costs incurred for potential acquisitions or similar transactions; other anticipated financial events; the effects of changing economic and competitive conditions, including instability in capital markets which could impact availability of short and long-term financing; the timing and extent of changes in interest rates; the level of borrowings; foreign exchange rates; government regulations; accreditation requirements; changes in the trading market that affect the costs of obligations under the Company’s benefit plans; and pending accounting pronouncements. These assumptions may not materialize to the extent assumed, and risks and uncertainties may cause actual results to be different from what is anticipated today. These risks and uncertainties also may result in changes to the Company’s business plans and prospects, and could create the need from time to time to write down the value of assets or otherwise cause the Company to incur unanticipated expenses. Additional information may be obtained by reviewing the information set forth in Item 1A. “Risk Factors” and Item 7A. “Quantitative and Qualitative Disclosures about Market Risk” of the Company’s Annual Report on Form 10-K for the year ended September 30, ~~2015~~2016 and information contained in other reports filed by the Company, from time to time, with the SEC. The Company does not undertake, and expressly disclaims, any duty to update any forward-looking statement whether as a result of new information, future events or changes in the Company’s expectations, except as required by law.

The Company is exposed to market risk, including changes in foreign currency exchange rates and is subject to interest rate risk related to borrowings under its existing credit facility. These risks are set forth in Item 7A. “Quantitative and Qualitative Disclosures about Market Risk” of the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, ~~2015.~~2016. The Company believes there have been no material changes in the information provided from the end of the preceding fiscal year through ~~June 30, 2016.~~March 31, 2017.

As of ~~June 30, 2016,~~March 31, 2017, an evaluation was performed under the supervision and with the participation of our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”) (the Company’s principal executive officer and principal financial officer, respectively), of the effectiveness of the design and operation of the Company’s “disclosure controls and procedures” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities and Exchange Act of 1934, as amended.

Based upon that evaluation, our CEO and CFO concluded that the Company’s disclosure controls and procedures were ~~not~~ effective ~~as a result of the previously reported material weaknesses that existed in our internal control over financial reporting described below.~~

~~A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is~~at a reasonable ~~possibility that a material misstatement~~assurance level for the purpose of ~~our annual or interim financial statements will not be prevented or detected on a timely basis.~~

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, orensuring that the ~~degree of compliance with~~information required to be disclosed by us in the ~~policies~~reports that we file or ~~procedures may deteriorate.~~

~~In prior filings, we identified~~submit under the Exchange Act is (a) recorded, processed, summarized and reported ~~material weaknesses~~within the time periods specified in the ~~Company’s internal control over financial reporting, which still exist as of June 30, 2016, due~~SEC’s rules and forms and (b) accumulated and communicated to ~~continued remediation and testing procedures. In response to the identified material weaknesses, our~~ management ~~with oversight from our audit committee, has dedicated significant resources to improve our control environment and to remedy the identified material weaknesses.~~

We believe that we have designed and implemented the appropriate controls to fully remediate the remaining material weaknesses. However, the Company is required to demonstrate the effectiveness of the new processes for a sufficient period of time. Therefore, until the actions set forth below, including the ~~efforts~~CEO and CFO, or persons performing similar functions, as appropriate to ~~implement and test the necessary control activities we identify, are fully completed, the following material weaknesses will continue to exist.~~

~~Control Environment~~ - We did not maintain an effective control environment as we did not maintain a sufficient complement of personnel with an appropriate level of knowledge of accounting, experience and training commensurate with our financial reporting requirements. Additionally, we did not consistently establish appropriate authorities and responsibilities in pursuit of our financial reporting objectives. These material weaknesses contributed to the following control deficiencies, each of which is considered to be a material weakness:

~~Remediation Activities:We have improved our IT general controls and segregation of duties. We have~~ adopted a new global IT general controls framework, and have implemented this new framework domestically. We have begun to implement this new framework in our European entities. In addition, we have removed access ~~to financial application programs and data beyond that needed for certain personnel to perform their individual job responsibilities.~~

~~Risk Assessment~~ - We did not design and implement effective risk assessment with regard to our processes and procedures commensurate with our financial reporting requirements. Specifically, we did not design and implement controls in response to risks of misstatement of the financial statements. This material weakness contributed to the following control deficiencies, each of which is considered to be a material weakness:

~~Remediation Activities:~~ ~~We have improved our controls to ensure the accurate and~~allow timely ~~reporting of revenue and the related receivables, including the following:~~

~~We commenced a formal risk assessment during fiscal 2015~~ ~~to assess risks and identify, design, implement, and re-evaluate our control activities and completed the risk assessment as of September 30, 2015.~~

The risk assessment and revenue material weaknesses also resulted in revisions to second and third quarter fiscal 2014, annual fiscal 2014 and first quarter fiscal 2015 financial statement disclosures related to sales to its equity investees. Management has determined that these revisions, first disclosed in the second quarter of fiscal 2015, are additional effects of the material weaknesses related to risk assessment and revenue described above.

Notwithstanding the identified material weaknesses, management believes the consolidated financial statements included in this Quarterly Report on Form 10-Q present fairly, in all material respects, our financial condition, results of operations and cash flows as of and for the periods presented in conformity with U.S. GAAP.decisions regarding required disclosure.

There has been no change in the Company’s internal control over financial reporting that occurred during the ~~third~~second quarter of fiscal ~~2016~~2017 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

The Company is a party, from time to time, to various legal proceedings, lawsuits and other claims arising in the ordinary course of its business. The Company does not believe that any such litigation pending as of ~~June 30, 2016,~~March 31, 2017, if adversely determined, would have a material effect on its business, financial position, results of operations, or cash flows.

Information regarding risk factors is set forth in Item 1A. “Risk Factors” of the ~~Company��s~~Company’s Annual Report on Form 10-K for the fiscal year ended September 30, ~~2015.~~2016. The Company believes there have been no material changes in the information provided from the end of the preceding fiscal year through ~~June 30, 2016~~March 31, 2017.

The Company’s purchases of its equity securities from the end of the preceding fiscal year through ~~June 30, 2016~~March 31, 2017 includes the deemed surrender of existing shares of Landauer common stock to the Company by stock-based compensation plan participants to satisfy the exercise price or tax liability of employee stock awards at the time of exercise or vesting. These surrendered shares are not part of any publicly announced share repurchase program.

Period

Total  Number of Shares  Purchased

Average  Price Paid  per Share

Total Number of  Shares Purchased  as Part of  Publicly  Announced  Plans  or Programs

Maximum  Number of  Shares that May  Yet be  Purchased  Under the Plans  or Programs
October 1 - October 31, 2015

608

$
39.58

-

-
November 1 - November 30, 2015

278

40.83

-

-
December 1 - December 31, 2015

433

37.01

-

-
Quarter ended December 31, 2015

1,319

$
39.00

-

-
January 1 - January 31, 2016

-

$
-

-

-
February 1 - February 29, 2016

342

29.12

-

-
March 1 - March 31, 2016

-

-

-

-
Quarter ended March 31, 2016

342

$
29.12

-

-
April 1 - April 30, 2016

1,157

$
33.35

-

-
May 1 - May 31, 2016

1,206

35.05

-

-
June 1 - June 30, 2016

-

-

-

-
Quarter ended June 30, 2016

2,363

$
34.22

-

-



Period	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares that May Yet be Purchased Under the Plans or Programs
October 1 - October 31, 2016	149	$	43.89	-	-
November 1 - November 30, 2016	-		-	-	-
December 1 - December 31, 2016	-		-	-	-
Quarter ended December 31, 2016	149	$	43.89	-	-
January 1 - January 31, 2017	375	$	50.30	-	-
February 1 - February 28, 2017	-		-	-	-
March 1 - March 31, 2017	-		-	-	-
Quarter ended March 31, 2017	375	$	50.30	-	-

~~Furnished with the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2016.~~

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


(Dollars in Thousands)	March 31, 2017		September 30, 2016
Segment assets:
Radiation Measurement	$	159,090	$	160,560
Medical Physics		44,311		43,174
Eliminations		(12,893)		(12,918)
Consolidated assets	$	190,508	$	190,816


(Dollars in Thousands)	June 30, 2016		September 30, 2015
Segment assets:
Radiation Measurement	$	161,305	$	142,850
Medical Physics		46,241		43,677
Medical Products		-		48,308
Eliminations		(12,876)		(26,091)
Consolidated assets	$	194,670	$	208,744

		Cer
31.1*10		Support Agreement, dated January 10, 2017, by and among the Registrant and Gilead Capital LP, Gilead Capital GP LCC and Jeffrey A. Strong is incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed January 12, 2017

31.1		Certification of Michael P. Kaminski, President and Chief Executive Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*31.2		Certification of Daniel J. Fujii, Chief Financial Officer, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*32.1		Certification of Michael P. Kaminski, President and Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2*32.2		Certification of Daniel J. Fujii, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS**101.INS		XBRL INSTANCE FILE

101.SCH**101.SCH		XBRL SCHEMA FILE

101.CAL**101.CAL		XBRL CALCULATION FILE

101.DEF**101.DEF		XBRL DEFINITION FILE

101.LAB**101.LAB		XBRL LABEL FILE

101.PRE**101.PRE		XBRL PRESENTATION FILE

8
		LANDAUER, INC.
		(Registrant)

Date: ~~August 8, 2016~~May 9, 2017		/s/ Daniel J. Fujii
		Daniel J. Fujii
		Chief Financial Officer


Period	Total Number of Shares Purchased	Average Price Paid per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares that May Yet be Purchased Under the Plans or Programs
October 1 - October 31, 2015	608	$	39.58	-	-
November 1 - November 30, 2015	278		40.83	-	-
December 1 - December 31, 2015	433		37.01	-	-
Quarter ended December 31, 2015	1,319	$	39.00	-	-
January 1 - January 31, 2016	-	$	-	-	-
February 1 - February 29, 2016	342		29.12	-	-
March 1 - March 31, 2016	-		-	-	-
Quarter ended March 31, 2016	342	$	29.12	-	-
April 1 - April 30, 2016	1,157	$	33.35	-	-
May 1 - May 31, 2016	1,206		35.05	-	-
June 1 - June 30, 2016	-		-	-	-
Quarter ended June 30, 2016	2,363	$	34.22	-	-